Pfizer dismissed from US states' drug price-fixing lawsuit
Key takeaways
- Pfizer dismissed from US states' drug price-fixing lawsuit FILE PHOTO: A Pfizer logo is shown at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025.
- June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
- These included generic versions of Eplerenone tablets for high blood pressure, Latanoprost drops for glaucoma, and four versions of Clindamycin phosphate for acne.
Pfizer dismissed from US states' drug price-fixing lawsuit FILE PHOTO: A Pfizer logo is shown at a research facility in the La Jolla neighborhood of San Diego, California, U.S., September 30, 2025. REUTERS/Mike Blake/File Photo · Reuters By Jonathan Stempel Wed, June 24, 2026 at 9:55 PM GMT+7 2 min read PFE SDZ.SW By Jonathan Stempel
June 24 (Reuters) - Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
In a decision on Tuesday, Chief Judge Michael Shea of the federal district court in Connecticut said the states failed to show that Pfizer and its former Greenstone unit conspired with rivals between 2010 and 2014 to rig bids and allocate customers for six drug products.